@article{53761440b0c64ebd8d4a2d04d1d84352,
title = "Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya",
abstract = "Background: Since special efforts are necessary to vaccinate people living far from fixed vaccination posts, decision makers are interested in knowing the economic value of such efforts. Methods: Using our immunization geospatial information system platform and a measles compartment model, we quantified the health and economic value of a 2-dose measles immunization outreach strategy for children <24 months of age in Kenya who are geographically hard-to-reach (i.e., those living outside a specified catchment radius from fixed vaccination posts, which served as a proxy for access to services). Findings: When geographically hard-to-reach children were not vaccinated, there were 1427 total measles cases from 2016 to 2020, resulting in $9.5 million ($3.1–$18.1 million) in direct medical costs and productivity losses and 7504 (3338–12,903) disability-adjusted life years (DALYs). The outreach strategy cost $76 ($23–$142)/DALY averted (compared to no outreach) when 25% of geographically hard-to-reach children received MCV1, $122 ($40-$226)/DALY averted when 50% received MCV1, and $274 ($123-$478)/DALY averted when 100% received MCV1. Conclusion: Outreach vaccination among geographically hard-to-reach populations was highly cost-effective in a wide variety of scenarios, offering support for investment in an effective outreach vaccination strategy.",
keywords = "Economic, Hard-to-reach populations, Vaccination",
author = "Lee, {Bruce Y.} and Brown, {Shawn T.} and Haidari, {Leila A.} and Samantha Clark and Taiwo Abimbola and Pallas, {Sarah E.} and Wallace, {Aaron S.} and Mitgang, {Elizabeth A.} and Jim Leonard and Bartsch, {Sarah M.} and Yemeke, {Tatenda T.} and Eli Zenkov and Sachiko Ozawa",
note = "Funding Information: Research reported in this publication was supported by the Centers for Disease Control and Prevention (CDC) via contract 200-2015-M-63169 , the International Society for Infectious Diseases (ISID) and Pfizer via the SIGMA grant and the Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317 , the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Office of Behavioral and Social Sciences Research (OBSSR) and the Global Obesity Prevention Center (GOPC) via grant U54HD070725 , NICHD via grant U01HD086861 , and the National Institute for General Medical Science (NIGMS) via the MIDAS 5U24GM110707 grant. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Funding Information: Research reported in this publication was supported by the Centers for Disease Control and Prevention (CDC) via contract 200-2015-M-63169, the International Society for Infectious Diseases (ISID) and Pfizer via the SIGMA grant and the Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Office of Behavioral and Social Sciences Research (OBSSR) and the Global Obesity Prevention Center (GOPC) via grant U54HD070725, NICHD via grant U01HD086861, and the National Institute for General Medical Science (NIGMS) via the MIDAS 5U24GM110707 grant. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",
year = "2019",
month = apr,
day = "17",
doi = "10.1016/j.vaccine.2019.03.007",
language = "English (US)",
volume = "37",
pages = "2377--2386",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",
}